UNCY NASDAQ
Unicycive Therapeutics, Inc.
1W: -0.2%
1M: -1.9%
3M: -31.2%
YTD: -8.8%
1Y: +23.3%
3Y: -33.0%
5Y: -81.0%
$5.29
-0.02 (-0.38%)
Weekly Expected Move ±5.8%
$5
$5
$5
$6
$6
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$141.2M
52W Range3.71-8.74
Volume1,116,654
Avg Volume1,276,665
Beta1.78
Dividend—
Analyst Ratings
Company Info
CEOShalabh K. Gupta
Employees21
SectorHealthcare
IndustryBiotechnology
IPO Date2021-07-12
Websiteunicycive.com
1975 West El Camino Real
Mountain View, CA 94040
US
Mountain View, CA 94040
US
650 351 4495
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Latest News
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
Noble Financial Has Positive Forecast for UNCY Q3 Earnings
Research Analysts Set Expectations for UNCY Q3 Earnings
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Kenkare-Mitra Sara | A-Award | 47,941 | — | 2026-05-14 |
| Laumas Sandeep | A-Award | 47,941 | — | 2026-05-14 |
| Gupta Shalabh K. | A-Award | 762,200 | — | 2026-05-14 |
| Kenkare-Mitra Sara | A-Award | 84,200 | — | 2026-05-14 |
| Kenkare-Mitra Sara | A-Award | 42,100 | — | 2026-05-14 |